Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009

Journal of Law, Medicine and Ethics

Volumn 41, Issue 3, 2013, Pages 688-696

  Outterson, Kevin ^a   Powers, John H ^b   Seoane Vazquez, Enrique ^c,d   Rodriguez Monguio, Rosa ^e   Kesselheim, Aaron S ^f  

^a BOSTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Division of Pharmaceutical Sciences   (United States)

^d MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; DRUG APPROVAL; DRUG RECALL; FOOD AND DRUG ADMINISTRATION; HUMAN; STATISTICS; UNITED STATES;

ANTI-INFECTIVE AGENTS; DRUG APPROVAL; HUMANS; SAFETY-BASED DRUG WITHDRAWALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84885102013     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12079     Document Type: Article

References (39)

1. M. Lipsitch and M. H. Samore, "Antimicrobial Use and Antimicrobial Resistance: A Population Perspective," Emerging Infectious Disease 8, no. 4 (2002): 347-354;
2. E. Klein, D. L. Smith, and R. Laxminarayan, "Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus Aureus, United States, 1999-2005," Emerging Infectious Disease 13, no. 12 (2007): 1840-1846;
3. F. Baquero, T. M. Coque, F. de la Cruz, "Ecology and Evolution as Targets: The Need for Novel Eco-Evo Drugs and Strategies to Fight Antibiotic Resistance," Antimicrobial Agents and Chemotherapy 55, no. 8 (2011): 3649-3660.
4. A. S. Kesselheim and K. Outterson, "Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals," Health Affairs 29, no. 9 (2010): 1689-1696;
5. R. Laxminarayan and A. Malani, "Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance," Resources for the Future, 2007, available at (last visited July 26, 2013);
6. A. S. Kesselheim and K. Outterson, "Improving Antibiotic Markets for Long Term Sustainability," Yale Journal of Health Policy, Law and Ethics 11, no. 1 (2011): 101-167;
7. K. Outterson, J. B. Samora, and K. Keller-Cuda, "Will Longer Antimicrobial Patents Improve Global Public Health?" The Lancet Infectious Disease 7, no. 8 (2007): 559-566;
8. A. D. So, N. Gupta, S. K. Brahmachari, I. Chopra, B. Munos, C. Nathan, K. Outterson, J. P. Paccaud, D. J. Payne, R. W. Peeling, M. Spigelman, and J. Weigelt, Towards New Business Models for R and D for Novel Antibiotics Drug Resistance Updates 14, no. 2 (2011): 88-94.
9. Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS), Infection Control and Hospital Epidemiology 33, no. 4 (2012): 322-327 [hereinafter cited as Policy Statement].
10. ECDC/EMEA, Joint Technical Report: The Bacterial Challenge: Time to React-A Call to Narrow the Gap between Multidrug- Resistant Bacteria in the EU and the Development of New Antibacterial Agents (2009), available at (last visited July 29, 2013);
11. B. Spellberg, J. H. Powers, E. P. Brass, L. G. Miller, and J. E. Edwards, Jr., "Trends in Antimicrobial Drug Development: Implications for the Future," Clinical Infectious Diseases 38, no. 9 (2004): 1279- 1286;
12. Infectious Diseases Society of America, Bad Bugs, No Drugs: As Antibiotic Discovery Stagnatesa Public Health Crisis Brews (2004), available at (last visited July 29, 2013);
13. L. Freire-Moran, B. Aronsson, C. Manz, I. C. Gyssens, A. D. So, D. L. Monnet, O. Cars, ECDC-EMA Working Group, "Critical Shortage of New Antibiotics in Development against Multidrug-Resistant Bacteria-Time to React Is Now," Drug Resistance Updates 14, no. 2 (2011): 118-124;
14. Swedish Presidency of the European Union, Innovative Incentives for Effective Antibacterials, Stockholm, Sweden, September 17, 2009, available at (last visited August 14, 2013);
15. S. J. Projan, "Why Is Big Pharma Getting Out of Antibacterial Drug Discovery?" Current Opinion in Microbiology 6, no. (2003): 427-430.
16. B. Munos, "Lessons from 60 Years of Pharmaceutical Innovation," Nature Reviews Drug Discovery 8, no. 12 (2009): 959-968.
17. F. Allerberger, R. Gareis, V. Jindrak, and M. J. Struelens, "Antibiotic Stewardship Implementation in the EU: The Way Forward," Expert Review of Anti- Infective Therapy 7, no. 10 (2009): 1175-1183.
18. Alliance for the Prudent Use of Antibiotics (APUA) Clinical Newsletter 30, no. 1 (2012): 13-15.
19. T. Kirby, "Europe to Boost Development of New Antimicrobial Drugs," The Lancet 379, no. 9833 (2012): 2229-2230;
20. E. Mossialos, C. M. Morel, S. Edwards, J. Berenson, M. Gemmill-Toyama, and D. Brogan, Policies and Incentive for Promoting Innovation in Antibiotic Research, 2010 World Health Organization, on behalf of the European Observatory on Health Systems and Policies, available at (last visited July 29, 2013).
21. K. Outterson, J. H. Powers, I. M. Gould, and A. S. Kesselheim, "Questions about the 10 x '20 Initiative," Clinical Infectious Diseases 51, no. 6 (2010): 751-752.
22. FDA, "Drugs FDA," available at (last visited August 14, 2013).
23. WHO Collaborating Centre for Drug Statistics Methodology, "Structure and Princples," available at (last visited August 14, 2013).
24. Z. P. Qureshi, E. Seoane-Vazquez, R. Rodriguez-Monguio, K. B. Stevenson, and S. L. Szeinbach, "Market Withdrawal of New Molecular Entities Approved in the United States from 1980 to 2009," Pharmacoepidemiology and Drug Safety 20 (2011): 772-777.
25. FDA/CDER/Office of Surveillance and Epidemiology, Levaquin (Levofloxacin) Oral Solution, 250 mg/10 ml BPCA Drug Use Review, July 10, 2008, available at (last visited July 29, 2013);
26. D. K. Wysowski and L. Swartz, "Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions," Archives of Internal Medicine 165, no. 12 (2005): 1363-1369;
27. P. Olivier and J. L. Montastruc, "The Nature of the Scientific Evidence Leading to Drug Withdrawals for Pharmacovigilance Reasons in France," Pharmacoepidemiology and Drug Safety 15, no. 11 (2006): 808-812;
28. J. Lexchin, "Drug Withdrawals from the Canadian Market for Safety Reasons, 1963-2004," CMAJ 172, no. (2005): 765-767;
29. H. H. Liu, "Safety Profile of the Fluoroquinolones: Focus on Levofloxacin," Drug Safety 33, no. 5 (2010): 353- 369;
30. A. M. Issa, K. A. Phillips, S. Van Bebber, H. G. Nidamarthy, K. E. Lasser, J. S. Haas, B. K. Alldredge, R. M. Wachter, and D. W. Bates, "Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends," Current Drug Safety 2, no. 3 (2007): 177-185;
31. O. M. Bakke, M. Manocchia, F.de Abajo, K. I. Kaitin, and L. Lasagna, "Drug Safety Discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A Regulatory Perspective," Clinical Pharmacology & Therapeutics 58, no. 1 (1995): 108-17.
32. US Government Accountability Office, FDA's Consideration of Evidence from Certain Clinical Trials, July 2010, available at (last visited August 14, 2013);
33. FDA, Guidance for Industry, Antibacterial Drug Products: Use of Noninferiority Trials to Support Approval, November 2010, available at (last visited August 14, 2013).
34. C. Pulcini, K. Bush, W. A. Craig, N. Frimodt-Moller, M. Grayson, J. W. Mouton, J. Turnidge, S. Harbarth, and I. C. Gyssens, "ESCMID Study Group for Antibiotic Policies. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia," Clinical Infectious Diseases 54, no. 2 (2012): 268-274.
35. M. Hunt, Changing Patterns of Pharmaceutical Innovation (May 2002), National Institute for Health Care Management (NIHCM) Research and Educational Foundation, available at (last visited July 29, 2013).
36. J. Love, Knowledge Ecology International, "Prizes to Stimulate Innovation," available at (last visited August 14, 2013).
37. G. A. Breen and W. L. St. Peter, "Hypoprothrombinemia Associated with Cefmetazole," Annals of Pharmacotherapy 31, no. (1997): 180-184;
38. J. J. Lipsky, "Antibiotic-Associated Hypoprothrombinemia," Journal of Antimicrobial Chemotherapy 21 (1988): 281-300;
39. R. B. Brown, J. Klar, and S. Lemeshow et al., "Enhanced Bleeding with Cefoxitin and Moxalactam," Archives of Internal Medicine 146 (1986): 2159-2164.